METASTATIC SOLID TUMOR

This early-stage study is testing a new oral drug called ART6043, both by itself and combined with an existing cancer drug (olaparib), in people with advanced or spreading solid tumors. The main goals are to find safe doses and see early signs of whether the treatment helps contr…

This study tested an experimental drug called sacituzumab govitecan in people with advanced solid tumors that had spread and stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and control the cancer. Researchers measured how many people…

This is a first-in-human study to test the safety and early effectiveness of a new drug called WTX-124, given alone and in combination with an existing immunotherapy (pembrolizumab). It will enroll about 150 adults with advanced or metastatic solid tumors, such as melanoma or kid…

This is a first-in-human study to check the safety of a new, personalized cell therapy called M-CENK, given with a drug named N-803, for adults with advanced solid tumors that have spread or stopped responding to other treatments. The therapy involves collecting a patient's own i…

This early-stage study is testing a new drug called DCC-3116, both by itself and combined with other cancer drugs, for people with advanced solid tumors that have specific genetic changes. The main goals are to find safe doses and see if the treatments can shrink tumors. It is fo…

This is the first study in humans testing a new drug called DS-1055a. It aims to find a safe dose and check for side effects in 40 adults with advanced solid tumors that have returned or stopped responding to available treatments. The main goal is to understand how the body handl…

This early-stage trial is testing a new long-acting immunotherapy drug called TransCon IL-2 β/γ in adults with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe doses and see if the drug, given alone or with other cancer treatment…

This is an early-stage trial to test the safety and determine the right dose of a new experimental drug called LY4066434. The drug is designed to block a common cancer-driving protein called KRAS in people with advanced solid tumors, including pancreatic, lung, and colorectal can…

This study looks back at medical records to understand how well immunotherapy cancer drugs work for American Indian patients compared to White patients. Researchers will analyze survival times, side effects, and cancer-related deaths in 72 patients who were treated between 2015 a…